<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01902251</url>
  </required_header>
  <id_info>
    <org_study_id>9785-CL-0003</org_study_id>
    <nct_id>NCT01902251</nct_id>
  </id_info>
  <brief_title>Relative Bioavailability Study of Enzalutamide in Prostate Cancer Patients</brief_title>
  <official_title>A Phase I, Open-label, Randomized, Parallel, Relative Bioavailability Study Comparing a Capsule and a Tablet Formulation of Enzalutamide Following Multiple Once Daily Doses of 160 mg Enzalutamide in Male Subjects With Prostate Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Europe B.V.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Medivation, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A multiple dose relative bioavailability study in patients with prostate cancer comparing a
      capsule and a tablet formulation of enzalutamide.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <completion_date type="Actual">October 2013</completion_date>
  <primary_completion_date type="Actual">October 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pharmacokinetic profile of Enzalutamide under fasted conditions measured by Cmax (Maximum concentration)</measure>
    <time_frame>Day1 through Day 56 (12 samples)</time_frame>
    <description>Day 56 (fasted) Cmax under steady state conditions of enzalutamide</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Pharmacokinetic profile of Enzalutamide under fasted conditions measured by AUC0-24h (Area under the concentration-time curve 0-24h)</measure>
    <time_frame>Day1 through Day 56 (12 samples)</time_frame>
    <description>Day 56 (fasted) AUC0-24h under steady state conditions of enzalutamide</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of Enzalutamide under fasted and fed conditions</measure>
    <time_frame>Day 1, 8, 29, 55, 56 and 57 (38 samples)</time_frame>
    <description>Measured by: Cmax, tmax (Time to attain Cmax), AUC0-24h, Ctrough (Trough concentration), PTR (Peak-trough ratio), CLss/F (Apparent clearance at steady state)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic profile of MDPC0001 alone, MDPC0002 alone and sum of Enzalutamide plus MDPC0002</measure>
    <time_frame>Day 8, 29, 55, 56 and 57 (26 samples)</time_frame>
    <description>Measured by: Ctrough, Cmax, tmax, AUC0-24h, Ctrough (24h after dosing), PTR</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Evaluation of the safety and tolerability of two oral formulations of Enzalutamide assessed through vital signs, adverse events, electrocardiogram and clinical laboratory assessments</measure>
    <time_frame>Day 1 through Day 58</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">27</enrollment>
  <condition>Prostate Cancer</condition>
  <condition>Pharmacokinetics of Enzalutamide</condition>
  <arm_group>
    <arm_group_label>Enzalutamide tablet</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Multiple once daily oral doses of enzalutamide formulated as a tablet for approximately 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Enzalutamide capsule</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Multiple once daily oral doses of enzalutamide formulated as liquid-filled soft gelatin capsule for approximately 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide tablet</intervention_name>
    <description>Oral</description>
    <arm_group_label>Enzalutamide tablet</arm_group_label>
    <other_name>Xtandi</other_name>
    <other_name>MDV3100</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enzalutamide capsule</intervention_name>
    <description>Oral</description>
    <arm_group_label>Enzalutamide capsule</arm_group_label>
    <other_name>Xtandi</other_name>
    <other_name>MDV3100</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Histologically confirmed prostate cancer (all stages) for whom androgen deprivation
             therapy is indicated (except when indicated in a neoadjuvant/adjuvant setting).
             Subjects may be on ongoing androgen deprivation therapy with a gonadotropin releasing
             hormone (GnRH) analogue or orchiectomy (i.e., medical or surgical castration) at study
             entry.

          -  Progressive disease by Prostate-specific antigen (PSA) or imaging. Disease progression
             for study entry is defined as one or more of the following 3 criteria:

               -  PSA progression defined by a minimum of 2 rising PSA levels with an interval of
                  ≥1 week between each determination. The PSA value during the pre-investigational
                  period should be ≥2 μg/L (2 ng/mL);

               -  Soft tissue disease progression defined by the Response Evaluation Criteria in
                  Solid Tumors, version 1.1 (RECIST 1.1) for soft tissue disease

               -  Bone disease progression defined by two or more new lesions on bone scan

        Exclusion Criteria:

          -  Treatment with chemotherapy within 4 weeks prior to enrollment (Day 1 visit) or plans
             to initiate treatment with chemotherapy during the study.

          -  History of seizure or any condition that may predispose to seizure. Also, history of
             loss of consciousness, or transient ischemic attack within 12 months prior to
             enrollment (Day 1 visit).

          -  Patients who previously received treatment with Enzalutamide.

          -  Concomitant use of drugs that are potent inducers and/or inhibitors of CYP3A4 and
             CYP2C8.

          -  Confirmed CYP2C8 poor metabolizer status based on genotyping analysis.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Europe B.V.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Colorado - Anschutz Medical Campus</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Chicago Medical Center</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>60637</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh Medical Center</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.clinicaltrials.jp/user/ctrSearch_e.jsp</url>
    <description>Link to Results on JAPIC - enter 140588 in the JapicCTI-RNo. field</description>
  </link>
  <verification_date>September 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 15, 2013</study_first_submitted>
  <study_first_submitted_qc>July 15, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 18, 2013</study_first_posted>
  <last_update_submitted>September 8, 2014</last_update_submitted>
  <last_update_submitted_qc>September 8, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 9, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Prostate cancer</keyword>
  <keyword>Bioavailability</keyword>
  <keyword>Food effect</keyword>
  <keyword>Pharmacokinetics</keyword>
  <keyword>Xtandi</keyword>
  <keyword>Enzalutamide</keyword>
  <keyword>MDV3100</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

